Paul Richardson, MD

In this closing segment, Drs Paul Richardson and Hans Lee look ahead to how BCMA-directed bispecific antibodies may continue to evolve within an increasingly complex treatment landscape.

The RRO highlights that isatuximab combined with RVd as induction therapy produced deep and rapid responses in transplant-eligible patients with newly diagnosed multiple myeloma. The regimen was generally well tolerated with a favorable safety profile, and early molecular responses were observed in a meaningful proportion of patients.

Drs Paul Richardson and Hans Lee discuss the evolving and often complex decisions around sequencing BCMA-directed therapies in multiple myeloma.

Drs Paul Richardson and Hans Lee address real-world strategies for managing cytokine release syndrome and how these considerations intersect with evolving treatment sequencing in multiple myeloma.

Drs Paul Richardson and Hans Lee compare the three currently available BCMA-directed bispecific antibodies and discuss how differences in administration, logistics, and emerging data influence treatment selection in relapsed or refractory multiple myeloma.

Drs Paul Richardson and Hans Lee focus on practical infection mitigation strategies for patients receiving BCMA-directed bispecific antibodies, with particular emphasis on the proactive use of intravenous immunoglobulin.

Drs Paul Richardson and Hans Lee focus on the safety profile of linvoseltamab and how its clinical features translate into real-world and community-based practice.

Drs Paul Richardson and Hans Lee walk through the pivotal LINKER-MM1 trial that supported the July 2025 approval of linvoseltamab for patients with relapsed or refractory multiple myeloma after multiple prior lines of therapy.

Exploring the complexities of treating refractory myeloma patients, highlighting the significance of BCMA as a therapeutic target and innovative treatment options.

Explore the latest advancements in treating relapsed and refractory myeloma, including innovative therapies and their real-world applications.

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.

Paul G. Richardson, MD, discusses the FDA approval of melphalan flufenamide in relapsed/refractory multiple myeloma.

Paul G. Richardson, MD, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the FDA approval of selinexor in multiple myeloma.

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the synergy between immunomodulators and proteasome inhibitors in the treatment of patients with relapsed/refractory multiple myeloma (RRMM).

Paul Richardson, MD, clinical program leader, director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the results of the OPTIMISMM trial in patients with multiple myeloma.